Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Non Operating Income (2021 - 2025)

Prime Medicine filings provide 5 years of Non Operating Income readings, the most recent being $7.1 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 254.61% to $7.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.0 million, a 26778.05% increase, with the full-year FY2025 number at $7.2 million, up 17480.49% from a year prior.
  • Non Operating Income hit $7.1 million in Q4 2025 for Prime Medicine, up from $3.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.1 million in Q4 2025 to a low of -$8.4 million in Q3 2021.
  • Median Non Operating Income over the past 5 years was $370000.0 (2022), compared with a mean of $113055.6.
  • Biggest five-year swings in Non Operating Income: crashed 395.32% in 2022 and later surged 19309.09% in 2023.
  • Prime Medicine's Non Operating Income stood at -$1.5 million in 2021, then crashed by 395.32% to -$7.2 million in 2022, then skyrocketed by 133.32% to $2.4 million in 2023, then tumbled by 291.58% to -$4.6 million in 2024, then skyrocketed by 254.61% to $7.1 million in 2025.
  • The last three reported values for Non Operating Income were $7.1 million (Q4 2025), $3.4 million (Q3 2025), and $18000.0 (Q2 2025) per Business Quant data.